Results 231 to 240 of about 125,716 (297)

Multi-omics reveals an association of the gut butyrate-IDO1-tryptophan axis with Yinchenhaotang plus Zexietang-ameliorated NASH in a microbiota-dependent manner. [PDF]

Chin Med
Liu W, Sha X, Zhao N, Liu B, Yang G, Jia L, Sui G.   +6 more
europepmc   +1 more source

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. [PDF]

Cell Host Microbe
Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B.   +11 more
europepmc   +1 more source

Deneysel nonalkolik steatohepatit modelinde genisteinin koruyucu rolü / Preventive role of genistein in experimental non-alcoholic steatohepatitis model

, 2005
Mehmet Yalnız
openalex   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Diet-induced steatohepatitis does not cause heart failure with preserved ejection fraction in male middle-aged C57BL/6N mice. [PDF]

PLoS One
Kessinger CW, Chen L, Huang F, Lin J, Davenport A, Lin Z.   +5 more
europepmc   +1 more source

Change in body mass index and disease burden among people with obesity and multiple long‐term conditions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a risk factor for multiple long‐term conditions (MLTCs/multimorbidity). However, the impact of weight loss in people with MLTCs is unclear. We investigated the association between body mass index (BMI) change and the development of obesity‐related complications (ORCs), as well as clinical and economic outcomes in individuals ...
Kamlesh Khunti, Alex Mourer, Silvia Capucci, Lua Wilkinson, Klaus K. Andersen, Abd A. Tahrani, Camilla S. Morgen   +6 more
wiley   +1 more source

Resmetirom and beyond: A new era in MASLD therapeutics. [PDF]

Liver Res
Johnson-Moore T, Simmons D, Okafor A, Washington D, Baskaran P.   +4 more
europepmc   +1 more source

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

Hepatology, 2013
Lixin Zhu, S. Baker, C. Gill, Wensheng Liu, Razan H. Alkhouri, R. Baker, S. Gill   +6 more
semanticscholar   +1 more source

Population‐based cohort validation and replication reveals limited generalizability of cluster‐based MASLD subtypes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims MASLD, defined as a steatotic liver disease in the presence of one or more cardiometabolic risk factors and the absence of harmful alcohol intake, exhibits substantial heterogeneity complicating risk stratification. A prior clustering model proposed liver‐specific and cardiometabolic subtypes, yet its generalizability and prognostic ...
Junjie Wu, Weiwei Xu, Guyu Zeng, Junfeng Wang   +3 more
wiley   +1 more source